Biotech & Pharma · Week of Nov 2, 2026
Q3 results reshape biotech pipelines: the week in Biotech & Pharma
Third-quarter results set pipeline and cash plans, while late-stage data at medical meetings and a Lilly telehealth pricing deal filled out the week.
Third-quarter reporting dominated the week. Perrigo cut its Core adjusted EPS outlook and agreed to sell its Infant Formula business, while smaller developers tied results to pipeline decisions. IDEAYA Biosciences said it is closing its Phase 3 OptimUM-010 trial after filing an NDA for darovasertib plus crizotinib. Q32 Bio plans a registration-directed program for bempikibart in 2027. Seres Therapeutics said its cash funds operations through the first quarter of 2027 as it designs a new SER-155 study.
Clinical data came from fall medical meetings. Johnson & Johnson presented Phase 3 psoriatic arthritis results for oral ICOTYDE at ACR Convergence 2026. Hengrui Pharma and Braveheart Bio reported 52-week data in obstructive hypertrophic cardiomyopathy at AHA. GLP-1 drugs appeared in two releases: Allergan Aesthetics studied aesthetic treatment in patients taking them, and Eli Lilly agreed with Hims & Hers to offer Zepbound and Foundayo at Lilly's self-pay prices on the telehealth platform.
Perrigo Company plc
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Perrigo reported third-quarter All In net sales down 5.2% to $989 million and a diluted loss per share of $(0.10), and lowered its fiscal 2026 Core adjusted EPS outlook to $2.15 to $2.35 from $2.25 to $2.55. After quarter-end it agreed to divest its Infant Formula business for up to $175 million, including $40 million upfront, and it cited retailer inventory positioning and softness in Europe in its updated outlook.
AbbVie
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Allergan Aesthetics, an AbbVie company, presented two Phase 4 studies at ASDS 2026 in adults on GLP-1 medications. In HARMONY IN DIVERSITY Cohort 2, FACE-Q facial appearance satisfaction improved by a mean 42.4 points, and in a HALO interim analysis of 25 participants it improved by 39.6 points, with most treatment-related adverse events mild and nonserious, the company says.
Eli Lilly and Company
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Eli Lilly and Hims & Hers agreed that eligible patients prescribed Zepbound or Foundayo by a licensed provider on the Hims & Hers platform can get Lilly's self-pay prices there, starting at $149 per month for Foundayo and $299 per month for Zepbound. Hims & Hers committed not to offer compounded copies of Lilly's GLP-1s, and the release gives no start date.
Johnson & Johnson
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Johnson & Johnson said once-daily oral ICOTYDE (icotrokinra) met the primary endpoint in the Phase 3 ICONIC-PsA 1 study. In biologic-naive adults with active psoriatic arthritis, 58% reached ACR20 at Week 16 versus 41% on placebo, with no new safety signals through Week 24. ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis but not for psoriatic arthritis.
Seres Therapeutics, Inc.
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)
Seres Therapeutics reported a third-quarter net loss of $16.3 million and had $17.5 million in cash as of September 30, plus a $12.5 million payment from Nestlé in October. It expects that cash to fund operations through the first quarter of 2027. It plans a funding-dependent study of SER-155 to prevent immune checkpoint inhibitor-related enterocolitis and expects to submit the design to the FDA in that same quarter.
IDEAYA Biosciences, Inc.
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences reported a third-quarter net loss of $125.7 million and said it submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma under Real-Time Oncology Review. It is closing the Phase 3 OptimUM-010 trial over enrollment challenges, with estimated savings of $100-125 million, plans two Phase 3 trials of IDE849 by year end, and kept cash runway guidance into 2030.
Q32 Bio
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported a third-quarter net loss of $8.9 million and cash of $289.6 million after a July offering with gross proceeds of about $200.0 million. It says bempikibart showed a 35.3% mean SALT score reduction at Week 36 in SIGNAL-AA Part B. It expects to begin a registration-directed program in severe or very severe alopecia areata in the first half of 2027, subject to regulatory discussions.
Braveheart Bio, Inc.
Hengrui Pharma and Braveheart Bio Present Data from52-Week Open-Label Extension of Phase 2 Studyof HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Hengrui Pharma and Braveheart Bio presented 52-week open-label extension data for the cardiac myosin inhibitor HRS/BHB-1893 in obstructive HCM at AHA 2026. In the 42 patients, pVO2 rose a mean 2.7 mL/kg/min and 79% had a Valsalva LVOT gradient below 30 mmHg. The companies reported no on-treatment severe or serious adverse events; two patients had transient LVEF reductions below 50%.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Times Beats reporting.